Compare Fastly Inc (FSLY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Novo Nordisk A/S — how do they compare? Fastly Inc trades at $28.92 (market cap $4.58B), while Novo Nordisk A/S trades at $46.26 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 45.4× Fastly Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Fastly Inc pays none. Which is the better fit depends on your goals.
| FSLY | NVO | |
|---|---|---|
Market Cap | $4.58B | $207.85B |
Sector | Technology | Health |
52-Week High | $33.50 | $63.98 |
52-Week Low | $6.85 | $35.29 |
Enterprise Value | $4.65B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FSLY trades at $29.39, up 5.89% today, near its 52-week high. The stock shows bullish technical signals with strong moving average support. Recent earnings beats, including Q2 2026 EPS of $0.15 versus $0.07 expected, and raised 2026 revenue guidance to $687M reflect robust execution. Security and AI demand are driving growth, though the company remains unprofitable with a net margin of -11.8%.
Outlook is positive due to accelerating revenue growth and AI tailwinds, but risks include persistent losses, high valuation at P/S of 6.38, and competitive pressures. Analysts are mixed with a $28.25 consensus target, slightly below current price, suggesting cautious optimism amid execution risks.
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
